Improve Medical Instruments Co (300030) Fair Value & Analysis
Healthcare · CN · Market cap 2.0B CNY
Fair value as of: Jul 7, 2026
From 24 valuation models · updated 34 days ago
Fair value updated Jul 7, 2026, revised from ¥1.47 to ¥1.03 (−29.9%) since Jun 24, 2026. Share price +11.7% over the past month.
A solid business, but screening 85% overvalued on our models.
What matters now
- The price sits above even our optimistic bull case (¥1.29). The favourable scenario is already priced in.
- Solid but not exceptional quality (67/100) and above fair value, neither a clear bargain nor a standout compounder.
Price vs Fair Value (5 years)
White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 7, 2026.
How to read this chart
60‑month range ¥3.34 – ¥12.45 · fair‑value band ¥0.7800 – ¥1.29 · the ¥6.89 price screens above the ¥1.03 fair value. Dashed = 300-day average. As of Jul 7, 2026.
Analysis
Improve Medical Instruments Co (300030) currently trades at ¥6.89, while our model-based Fair Value estimate is ¥1.03, implying the stock looks roughly 85.1% overvalued today. The Quality Score stands at 67/100 (solid quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: high).
Over the trailing twelve months, Improve Medical Instruments Co generated revenue of 466M CNY at a net margin of 6.1%. Revenue declined 17.5% year over year. It earns a return on equity of 4.4%. Net debt stands at 88.1M CNY. Fundamentals as of Jul 7, 2026
Our scenario range runs from ¥0.7800 (bear case) to ¥1.29 (bull case); at ¥6.89, the current price sits above that range. Bear and bull are the same models run on conservative and optimistic assumptions (margins, growth, valuation multiples), so a plausible valuation range, not a price target. The share trades about 30% below its 52-week high and 11% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -85%, 300030 screens richer than that median.
Fair Value models
Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.
All 24 models by family
Widest divergence: Growth DCF (¥2.65) versus Dividend Discount (¥0.1600). Highest evidence: Growth DCF (80).
Notify me when 300030 reaches fair value
Free. You confirm by email (double opt-in) and can unsubscribe anytime in one click.
Key figures & financial health
More key figures
Figures from reported company fundamentals · as of Jul 7, 2026. TTM = trailing twelve months.
Quality Score breakdown
Of which business quality 66 · Market factors (momentum, volatility) 34
Non-valuation factor families (profitability, growth, cashflow, financial strength, momentum …), each academically grounded. Valuation itself sits in the Fair Value and is deliberately excluded here to avoid double-counting.
About the company
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally.
Full company description
Improve Medical Instruments Co., Ltd. engages in the provision of relevant technologies, products, and services for clinical laboratory and clinical nursing in China and internationally. It provides clinical laboratory products comprising feces and thrombosis viscoelastic analysis systems; and automatic biosafety decappers; and Q-VELOX, an intelligent molecular diagnostic workstation. The company also offers offers specimen processing equipment, including evacuated blood collection systems, evacuated blood collection tubes, multi-sample needles, blood collection sets, tourniquets and disposable tourniquets, urine collection systems, and holders under IMPROVACUTER brand name; and IMPROMINI capillary blood collection systems, IMPROSWAB microbiological transportation systems, IMPRONURSE infusion pumps and syringe pumps, LONGX urine analysis systems, in-vitro diagnostic reagents, IMPROSAFE safety blood collection needles, IMPROVE sharps containers, liquid biopsy pre-analytical systems, etc. In addition, it provides clinical nursing products, including automatic, handheld, pulsewave, and smart wireless blood pressure monitors; and intelligent management solutions, such as blood collection tube preparation systems, friendly graphic user interfaces, intelligent sorters, multi-function blood collection tables, intelligent queue systems, urine collection tube preparation systems, automatic tube packer systems, and consumable labels, as well as CryoMax vials and liquid nitrogen freezing storage boxes. The company was formerly known as Guangzhou Improve Medical Instruments Co., Ltd. and changed its name to Improve Medical Instruments Co., Ltd. in December 2021. The company was founded in 1996 and is headquartered in Guangzhou, China.
Company description, as reported by the company or data provider.
Revenue & earnings trend
FY2021 – FY2025 · reported fiscal years
Improve Medical Instruments Co reported revenue of ¥486M in FY2025 versus ¥800M in FY2021, a compound −11.7%/yr. Reported net income was ¥14.5M in FY2025, compounding −5.9%/yr from FY2021.
300030 screens 85% overvalued. Compare with Intuitive Surgical, Inc →
Peer Group
Medical Instruments & Supplies · 203 stocks
How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.
Valuation Multiples vs Medical Instruments & Supplies median · lower = cheaper
Snowflake
Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.
VALUE 0: the price sits above our fair-value range.
Values & ESG
Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.
ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.
Similar stocks
10 more Medical Instruments & Supplies stocks, each showing price versus our Fair Value estimate (as of Jul 7, 2026).
| Stock | Price | Fair Value | vs Fair Value |
|---|---|---|---|
| Intuitive Surgical, Inc ISRG | $402.33 | $150.04 | -63% |
| EssilorLuxottica Société anonyme 1EL | €172.45 | €68.55 | -60% |
| Medline Inc MDLN | $41.11 | $30.15 | -27% |
| Becton, Dickinson and Company BDX | $150.65 | $103.53 | -31% |
| Alcon Inc ALC | $70.26 | $39.78 | -43% |
| ResMed Inc RMD | $203.87 | $187.89 | -8% |
| West Pharmaceutical Services, Inc WST | $353.71 | $143.97 | -59% |
| Straumann Holding STMN | CHF 106.00 | CHF 47.31 | -55% |
| Sartorius Stedim Biotech S.A DIM | €188.50 | €51.16 | -73% |
| Coloplast A/S COLOB | kr 414.00 | kr 382.22 | -8% |
Compare Improve Medical Instruments Co with another stock
Price, fair value, quality and upside side by side.
Explore undervalued stocks
More undervalued Healthcare stocks →
Frequently asked questions
Is Improve Medical Instruments Co (300030) overvalued or undervalued?
What is the fair value of 300030?
What is the quality score of 300030?
What is the revenue of Improve Medical Instruments Co (300030)?
What is the net profit margin of 300030?
How we calculate Fair Value
Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.
Track Improve Medical Instruments Co and try Pro for 14 days
One email gets you 14 days of full Pro (review alerts, the 35,000+ stock screener, the diversification check) plus the monthly Top-25 report of the most undervalued quality stocks. No card, cancel anytime.
Zero risk: nothing is ever charged. After 14 days you decide whether to stay.